A French biotech nabs Se­ries A to see if it can carve a role in the ADC space

No­body want­ed the patent.

Uni­ver­si­ty of Ly­on re­searchers had de­vel­oped a hy­drophilic drug-link­er plat­form for an­ti­body-drug con­ju­gates, now a hot field thanks to the likes of Pad­cev. War­ren Viri­cel, one piece of the Ly­on trio, had cre­at­ed Lina Ther­a­peu­tics. Along with pro­fes­sors Benoît Joseph and Charles Du­mon­tet, the three sci­en­tif­ic friends strug­gled to get the ball rolling, though.

In came Jean-Guil­laume Lafay.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER